Watanabe Todd Franklin's Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Dec 1, 2023
- Accession no.
- 0001787306-23-000129
- Filed
- Dec 1, 2023
- Trade date
- May 31-Dec 1, 2023
- Filing delay
- 184 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $9.33K. It was filed 184 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Watanabe Todd FranklinCIK 0001801061 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2023 | Common Stock | MOption exerciseAcquired | +59,525 | $1.68 | +$100,002 | 513,682 | Direct | |
| May 31, 2023 | Common Stock | PPurchaseAcquired | +1,463 | $6.38 | +$9,333.94 | 515,145 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2023 | Common Stock | MOption exerciseDisposed | −59,525 | $0.00 | $0 | 49,823 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Reporting Person's title: President and CEO.